Clinical Trials
8 trialsNCT05805605 2025-07-01
Allo HSCT Using RIC and PTCy for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Phase 2 Recruiting
NCT02661035 2023-09-21
Allo HSCT Using RIC for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT01685411 2021-04-13
Busulfan and Cyclophosphamide Followed By ALLO BMT
Masonic Cancer Center, University of Minnesota
Phase NA Terminated
NCT01200485 2020-01-31
Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01564277 2018-01-09
Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies
Roswell Park Cancer Institute
Phase 2 Terminated
NCT01464359 2017-12-28
T-Cell Depleted Double UCB for Refractory AML
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00513474 2017-05-25
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Massachusetts General Hospital
Phase 1 Completed
NCT00053196 2016-07-01
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed